Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Long-Term Debt Repayments (2016 - 2018)

Apyx Medical (APYX) has disclosed Long-Term Debt Repayments for 8 consecutive years, with $5.4 million as the latest value for Q4 2018.

  • For the quarter ending Q4 2018, Long-Term Debt Repayments rose 1189.0% year-over-year to $5.4 million, compared with a TTM value of $5.4 million through Sep 2019, up 336.73%, and an annual FY2023 reading of $11.0 million, changed N/A over the prior year.
  • Long-Term Debt Repayments was $5.4 million for Q4 2018 at Apyx Medical, up from -$2.8 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $6.6 million in Q4 2014 and bottomed at -$3.6 million in Q1 2014.
  • Average Long-Term Debt Repayments over 5 years is $281350.0, with a median of -$59000.0 recorded in 2016.
  • Peak annual rise in Long-Term Debt Repayments hit 11162.71% in 2014, while the deepest fall reached 10664.71% in 2014.
  • Year by year, Long-Term Debt Repayments stood at $6.6 million in 2014, then crashed by 106.31% to -$419000.0 in 2015, then soared by 85.68% to -$60000.0 in 2016, then surged by 796.67% to $418000.0 in 2017, then soared by 1189.0% to $5.4 million in 2018.
  • Business Quant data shows Long-Term Debt Repayments for APYX at $5.4 million in Q4 2018, -$2.8 million in Q3 2018, and $180000.0 in Q2 2018.